SAFETY AND IMMUNOGENICITY OF COLD-ADAPTED RECOMBINANT INFLUENZA VECTOR EXPRESSING ESAT-6 AND AG85А ANTIGENS OF M. TUBERCULOSIS-Reference-Cited by-同舟云学术

SAFETY AND IMMUNOGENICITY OF COLD-ADAPTED RECOMBINANT INFLUENZA VECTOR EXPRESSING ESAT-6 AND AG85А ANTIGENS OF M. TUBERCULOSIS

Published:2017-12-20 Issue:6 Volume:62 Page:266-272
ISSN:2411-2097
Container-title:Problems of Virology, Russian journal
language:
Short-container-title:Voprosy virusologii

Author:

Sergeeva M. V.¹,Pulkina A. A.²,Vasiliev K. A.¹,Romanovskaya-Romanko E. A.¹,Komissarov A. B.³,Kuchur O. A.⁴,Egorov A. Yu.¹,Tsybalova L. M.¹,Stukova M. A.¹

Affiliation:

1. Research Institute of Influenza

2. Research Institute of Influenza; Peter the Great St. Petersburg Polytechnic University

3. Research Institute of Influenza; St. Petersburg State University

4. St. Petersburg State University

Abstract

Recombinant viral vectors represent one of the most promising platforms for creating a new generation of vaccines against tuberculosis. We constructed a vaccine candidate based on a cold-adapted influenza vector with a truncated NS1 protein containing an insert of tuberculosis ESAT-6 and Ag85A antigens. The recombinant virus possessed a cold-adapted and temperature-sensitive phenotype and was attenuated for mice when administered intranasally. Immunofluorescent staining and Western blot showed the expression of ESAT-6 protein in MDCK cells infected by recombinant virus. After intranasal administration to mice, the recombinant virus stimulated a specific anti-tuberculosis CD4 + Th1-type response with the formation of polyfunctional antigen-specific T cells.

Publisher

Central Research Institute for Epidemiology

Subject

Infectious Diseases,Virology,General Medicine

Reference25 articles.

1. World Health Organization. Global Tuberculosis Report 2016. Available at: http://www.who.int/tb/publications/global_report/en/

2. World Health Organization. BCG vaccine. WHO position paper. Wkly Epidemiol. Rec. 2004; 79(4): 27-38.

3. Ottenhoff T.H., Kaufmann S.H. Vaccines against Tuberculosis: Where Are We and Where Do We Need to Go? PLoS Pathog. 2012; 8(5): e1002607.

4. Stukova M.A., Zabolotnykh N.V., Vinogradova T.I., Gergert V.Ya., Apt A.S., Kaprel'yants A.S. i dr. Profilaktika tuberkuleza: sovremennye podkhody k razrabotke protivotuberkuleznykh vaktsin. Vestnik Rossiiskoi akademii meditsinskikh nauk. 2012; (11): 45-52

5. Stukova M.A., Sereinig S., Zabolotnyh N.V., Ferko B., Kittel C., Romanova J., et al. Vaccine potential of influenza vectors expressing Mycobacterium tuberculosis ESAT-6 protein. Tuberculosis. 2006; 86(3-4): 236-46.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and Protective Efficacy of a Candidate Vector-Based Vaccine for Bovine Tuberculosis;Vaccines;2023-07-04

2. Vaccination Against Tuberculosis: Revamping BCG by Molecular Genetics Guided by Immunology;Frontiers in Immunology;2020-02-27

3. BCG and Novel Tuberculosis Vaccine Candidates in the Context of Immunodeficiencies;Encyclopedia of Medical Immunology;2020

4. BCG and Novel Tuberculosis Vaccine Candidates in the Context of Immunodeficiencies;Encyclopedia of Medical Immunology;2020

5. Neue Impfstoffe gegen Tuberkulose;Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz;2019-11-29